期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 128, 期 5, 页码 916-924出版社
WILEY
DOI: 10.1002/jso.27384
关键词
anaplastic lymphoma kinase; epidermal growth factor receptor; lung cancer; surgery; tyrosine kinase inhibitor
This study retrospectively analyzed data from the Japanese Joint Committee of Lung Cancer Registry database and found that ALK rearrangement was associated with improved long-term outcomes in surgically resected lung adenocarcinoma patients. Multivariable analysis revealed that ALK rearrangement was an independent prognostic factor for improved overall survival. In the postrecurrence state, the use of ALK-tyrosine kinase inhibitors improved survival.
Background and ObjectivesAnaplastic lymphoma kinase (ALK) rearrangement is a representative driver mutation in lung cancer. However, the biology of early-stage ALK-rearranged lung cancer remains unclear. We aimed to assess the clinicopathological features, prognostic implications, and influence of ALK rearrangement on the postoperative course in surgically resected lung cancer. MethodsWe retrospectively analyzed data from the Japanese Joint Committee of Lung Cancer Registry database. Of the 12 730 patients with lung adenocarcinoma, 794 (6.2%) were tested for ALK rearrangement and were included. ResultsALK rearrangements were detected in 76 patients (10%). The 5-year overall survival (OS) rate was significantly higher in the ALK rearrangement-positive group than in the ALK rearrangement-negative group (p = 0.030). Multivariable analysis revealed that ALK rearrangement was an independent prognostic factor for improved OS (hazard ratio, 0.521; 95% confidence interval, 0.298-0.911; p = 0.022). Regarding the postrecurrence state, there was no difference in the initial recurrence sites between both groups. Administration of ALK-tyrosine kinase inhibitors (TKIs) improved postrecurrence survival in any treatment lines. ConclusionIn one of the largest national surveys, ALK rearrangement was associated with improved long-term outcomes in surgically resected patients. ALK-TKIs may be an important treatment strategy for ALK rearrangement-positive lung adenocarcinoma in the postrecurrence state.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据